NASDAQ:CTNM Contineum Therapeutics Q1 2026 Earnings Report $15.04 +0.65 (+4.53%) As of 03:32 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Contineum Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.55Beat/MissN/AOne Year Ago EPSN/AContineum Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AContineum Therapeutics Announcement DetailsQuarterQ1 2026Date5/13/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Contineum Therapeutics Earnings HeadlinesContineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety BarMay 2, 2026 | msn.comContineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | businesswire.comWhy U.S. Bank CEOs Are Panicking Right NowWhy U.S. Bank CEOs Are Panicking Right Now Treasury Secretary Bessent and Fed Chair Powell recently summoned the CEOs of America's biggest banks to an emergency meeting over one AI lab's breakthrough. The Fed, Treasury, and virtually every major bank on Wall Street believes it could reshape the entire U.S. financial system. 60-Year Wall Street legend Marc Chaikin – whose system pinpointed Nvidia in 2014 before it soared 55,000% - has identified a way to invest in this lab for just $40 before it goes public. But you must act before June 15 to take full advantage of this pre-IPO "backdoor."May 6 at 1:00 AM | Chaikin Analytics (Ad)Contineum Therapeutics Reports Positive Phase 1b Chronic Pain DataApril 30, 2026 | tipranks.comContineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic PainApril 30, 2026 | businesswire.comWe Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business GrowthApril 19, 2026 | finance.yahoo.comSee More Contineum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Contineum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your email. Email Address About Contineum TherapeuticsContineum Therapeutics (NASDAQ:CTNM), a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.View Contineum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageDigitalOcean’s AI Surge: How Far Can This Rally Go?Years in the Making, AMD’s Upside Movement Has Just BegunCapital One’s Big Bet Faces Rising Credit RiskWestern Digital: The Storage Behemoth Skyrocketing on AI DemandOld Money, New Tech: Western Union's Crypto RebootHow Williams Companies Is Cashing in on the AI Power Boom Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)argenex (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
